<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> represent a prognostically diverse group of disorders </plain></SENT>
<SENT sid="1" pm="."><plain>Their study has recently been facilitated by the classification proposed by the French-American-British (FAB) Cooperative Group </plain></SENT>
<SENT sid="2" pm="."><plain>Using this scheme it is now possible to define more precisely their natural history and clinical relationship to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Using the longitudinal case control technique, we reviewed the clinical data and <z:mp ids='MP_0000002'>morphology</z:mp> of 69 patients (<z:hpo ids='HP_0000001'>all</z:hpo> elderly males) with <z:hpo ids='HP_0011010'>chronic</z:hpo> irreversible haematological cytopenia and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Applying FAB criteria we found: refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA) in 43%; sideroblastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA-S) in 33%; refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) in 13%; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) in 9% and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) in 1% </plain></SENT>
<SENT sid="5" pm="."><plain>The median survival for the entire group was 27 months (RA, 52; RA-S, 29; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 12; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> 11; and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, 2 months) </plain></SENT>
<SENT sid="6" pm="."><plain>Short survival was predicted by transfusion requirement and other manifestations of severe cytopenia, as well as by myeloid immaturity </plain></SENT>
<SENT sid="7" pm="."><plain>The presence or absence of <z:e sem="disease" ids="C0679425" disease_type="Disease or Syndrome" abbrv="">sideroblastosis</z:e> did not correlate with survival </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> developed in only eight patients (12%), six of whom initially had RA </plain></SENT>
<SENT sid="9" pm="."><plain>Leukaemic transformation was not predicted by progressive cytological immaturity </plain></SENT>
<SENT sid="10" pm="."><plain>This study demonstrates that even in the absence of leukaemic transformation, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> is a lethal haematological disorder </plain></SENT>
</text></document>